⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Orphalan SA and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Orphalan SA
↗Paris, France
Orphalan is an international, privately-owned pharmaceutical company headquartered in Paris, France, dedicated to the development and commercialization of innovative therapies for rare and debilitating diseases. Founded in 2011, the company focuses on addressing significant unmet medical needs by leveraging a global network of scientific and medical experts to deliver evidence-based treatments.
The company's flagship product is trientine tetrahydrochloride, a copper chelator used to treat Wilson's disease. It is marketed as Cuprior® in Europe and other regions, Cuvrior® in the United States, and Ke Pei Ou® in China. Orphalan emphasizes a patient-centric approach, aiming to reduce diagnostic delays and improve accessibility to orphan medicines worldwide.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2011
Ownership:private
Status:operating
FUNDING
Investors:Advent Life Sciences
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule
Trial Phases:Phase 3: 1
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Orphelia Pharma
Key Partnerships:MAP International (Humanitarian access), Wilson Disease Association (Advocacy/Education), SPH Kyuan Trade (China market access), Gustave Roussy (Pediatric oncology research)
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Naseem Amin - CEO
Alain Huriez - Chairman of the Board
Board Members:Shahzad Malik
LINKS
Website:orphalan.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Orphalan SA. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.